- Dosages
- Side effects in children
- Warnings & precautions in children
- Contra-indications in children
-
Interactions - PK
- Renal impairment
- References
Pharmacokinetics in children
No information is present at this moment.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
dose recommendation of formulary compared to licensed use (on-label versus off-label)
No information is present at this moment.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Available formulations
No information is present at this moment.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Dosages
| Mobilization of stem cells |
|---|
|
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Renal impaiment in children > 3 months
Adjustment in renal impairment as specified:
GFR 50-80 ml/min/1.73 m2
Dose adjustment not neededGFR 30-50 ml/min/1.73 m2
67 percentage of single dose and dosing interval : 24 uurGFR 10-30 ml/min/1.73 m2
67 percentage of single dose and dosing interval : 24 uurGFR < 10 ml/min/1.73 m2
A general recommendation is not providedClinical consequences
With impaired renal function, the AUC of plerixafor increases and the half-life is prolonged. As a result, the risk of adverse reactions is increased.
Clinical implications:
In a study with adult volunteers, the AUC of plerixafor increased by 7% at creatinine clearance 51-80 ml/min, 34% at creatinine clearance 31-50 ml/min, and 38% at creatinine clearance ≤ 30 ml/min. Cmax was not affected by renal function.[MacFarland 2010]
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here
Side effects in children
Side effects in children do not differ from adults.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here
Contra-indications
No information available on specific contra indications in children.
The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here
Warnings & precautions
No information available on specific warnings and precautions in children.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Interactions
The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
| Colony stimulating factors | ||
|---|---|---|
| L03AA02 | ||
| L03AA14 | ||
| Interferons | ||
|---|---|---|
| L03AB05 | ||
| L03AB11 | ||
| L03AB10 | ||
| Other immunostimulants | ||
|---|---|---|
| L03AX13 | ||
| L03AX15 | ||
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
References
- Genzyme Europe BV, SmPC Mozobil (EU/1/09/537/001) 02-09-2019
- NKFK Werkgroep nierfunctiestoornissen, Extrapolatie van KNMP risico analyse "Verminderde nierfunctie" voor volwassenen naar kinderen, 20 Dec 2021
- MacFarland R., A pharmacokinetic study of plerixafor in subjects with varying degrees of renal impairment., Biol Blood Marrow Transplant, 2010, 16, 95-101
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Changes
Changes
